Get the Stockscreener App
18.57
2.26%
-0.43
Newamsterdam Pharma Company Nv stock is traded at $18.57, with a volume of 559.57K.
It is down -2.26% in the last 24 hours and down -21.65% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$19.00
Open:
$19.21
24h Volume:
559.57K
Relative Volume:
0.64
Market Cap:
$1.99B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-8.6372
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
-6.73%
1M Performance:
-21.65%
6M Performance:
+14.14%
1Y Performance:
-13.87%
1-Day Range:
$18.31
$19.21
1-Week Range:
$18.31
$20.46
52-Week Range:
$15.19
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
18.57 | 1.99B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
Newamsterdam pharma COO sells shares worth $1.8 million - Investing.com
How To Trade (NAMS) - Stock Traders Daily
Mirae Asset Global Investments Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
abrdn plc Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
How to Take Advantage of moves in (NAMSW) - Stock Traders Daily
Newamsterdam pharma CFO sells shares worth $1.5 million - MSN
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NAMS: Strategic Executive Compensation Plan Unveiled138K Shares at $21.36 - StockTitan
Where are the Opportunities in (NAMS) - Stock Traders Daily
Make Informed Decisions with NewAmsterdam Pharma Company NV (NAMS) Stock Updates - The News Heater
Ratios Uncovered: Breaking Down NewAmsterdam Pharma Company NV (NAMS)’s Trailing Twelve Months Metrics - The Dwinnex
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
Results from NewAmsterdam Pharma Company NV (NAMS) show risk - US Post News
China Universal Asset Management Co. Ltd. Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
H.C. Wainwright initates NewAmsterdam Pharma Company NV (NAMS) rating to a Buy - Knox Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1%Still a Buy? - MarketBeat
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
JPMorgan Chase & Co. Increases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
How To Trade (NAMSW) - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownTime to Sell? - MarketBeat
Newamsterdam pharma's COO sells $3.1 million in stock - MSN
Newamsterdam pharma CFO sells shares worth $1.5 million By Investing.com - Investing.com Australia
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co. - Defense World
NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference - The Manila Times
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trials - MSN
Trend Tracker for (NAMS) - Stock Traders Daily
Royal Bank of Canada Reaffirms “Outperform” Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma's (NAMS) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC - Defense World
Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $39.80 - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $39.80 Consensus Price Target from Analysts - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%What's Next? - MarketBeat
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC Wainwright - MarketBeat
NewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2 - Defense World
NewAmsterdam gears up for obicetrapib regulatory filings By Investing.com - Investing.com Australia
NewAmsterdam gears up for obicetrapib regulatory filings - Investing.com India
NewAmsterdam Pharma Achieves Key Milestones in 2024 - TipRanks
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Newamsterdam Pharma Company Nv Stock (NAMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Somaiya Mayur Ian | Chief Financial Officer |
Jan 28 '25 |
Option Exercise |
9.26 |
14,900 |
137,974 |
52,900 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):